Published in Curr Pharm Des on January 01, 2008
Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats. Br J Pharmacol (2014) 0.84
Upregulation of CB₁ receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure. Behav Brain Res (2012) 0.81
Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem (2009) 0.79
Δ9-tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity. PLoS One (2014) 0.75
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry (2011) 2.25
Peripheral blood dendritic cells and monocytes are differently regulated in the elderly. Clin Immunol (2006) 1.69
Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) (2007) 1.65
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther (2005) 1.56
Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology (2008) 1.44
Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus (2009) 1.40
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J (2006) 1.36
A molecular basis of analgesic tolerance to cannabinoids. J Neurosci (2007) 1.28
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol (2005) 1.23
Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav (2005) 1.22
A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J (2004) 1.21
Adolescent exposure to cannabis as a risk factor for psychiatric disorders. J Psychopharmacol (2011) 1.21
Endocannabinoids link feeding state and auditory perception-related gene expression. J Neurosci (2004) 1.18
Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.16
Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology (2005) 1.12
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther (2003) 1.12
Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) (2007) 1.12
Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry (2007) 1.09
Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Br J Pharmacol (2009) 1.07
Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology (2005) 1.06
Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci (2007) 1.03
Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem (2005) 1.02
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend (2002) 1.00
Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology (2007) 1.00
Cannabidiol as potential anticancer drug. Br J Clin Pharmacol (2013) 1.00
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol (2005) 0.99
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol (2010) 0.98
Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol Neurobiol (2006) 0.97
Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology (2005) 0.97
Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology (2003) 0.96
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem (2005) 0.96
SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance. Nat Neurosci (2012) 0.96
Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci (2004) 0.95
Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. J Virol Methods (2006) 0.94
Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. Br J Pharmacol (2004) 0.93
Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology (Berl) (2005) 0.93
Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. Eur J Neurosci (2004) 0.92
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis (2005) 0.92
Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci (2011) 0.91
ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci (2006) 0.89
AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol (2012) 0.87
Cannabimimetic activity, binding, and degradation of stearoylethanolamide within the mouse central nervous system. Mol Cell Neurosci (2002) 0.87
Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol (2008) 0.87
Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology (2008) 0.87
Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. Int J Neuropsychopharmacol (2010) 0.87
Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators. J Biol Chem (2007) 0.87
Long-term consequences of URB597 administration during adolescence on cannabinoid CB1 receptor binding in brain areas. Brain Res (2008) 0.85
Intrauterine position has long-term influence on brain mu-opioid receptor density and behaviour in mice. Psychoneuroendocrinology (2003) 0.83
Chronic treatment with polychlorinated biphenyls (PCB) during pregnancy and lactation in the rat: Part 1: Effects on somatic growth, growth hormone-axis activity and bone mass in the offspring. Toxicol Appl Pharmacol (2009) 0.82
Transcriptomic and proteomic analyses of mouse cerebellum reveals alterations in RasGRF1 expression following in vivo chronic treatment with delta 9-tetrahydrocannabinol. J Mol Neurosci (2008) 0.82
Cannabinoids and opioids share cAMP pathway in rat splenocytes. J Neuroimmunol (2003) 0.82
Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol (2010) 0.79
Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. PLoS One (2013) 0.79
Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sci (2004) 0.79
Sex-dependent changes in brain CB1R expression and functionality and immune CB2R expression as a consequence of maternal deprivation and adolescent cocaine exposure. Pharmacol Res (2013) 0.78
Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. Eur J Pharmacol (2002) 0.78
Binding of δ9-tetrahydrocannabinol and diazepam to human serum albumin. IUBMB Life (2011) 0.78
In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. Pharmacol Res (2009) 0.77
Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. ChemMedChem (2012) 0.77
Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. Eur J Med Chem (2012) 0.76
Adaptation of NS cells growth and differentiation to high-throughput screening-compatible plates. BMC Neurosci (2010) 0.76
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects. Br J Pharmacol (2015) 0.76
The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des (2012) 0.76
Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress. Cancers (Basel) (2010) 0.75
Estrogenic effect of procymidone through activation of MAPK in MCF-7 breast carcinoma cell line. Life Sci (2005) 0.75
[Adolescent cannabis consumption and schizophrenia: epidemiological and experimental evidences]. Adicciones (2010) 0.75